ARTICLE | Clinical News

Neotrofin leteprinim: NEOT began a U.S. placebo-controlled Phase II trial of Neotrofin in 50 patients with ovarian cancer who are receiving carboplatin and pacl

January 14, 2002 8:00 AM UTC

NeoTherapeutics Inc. (NEOT), Irvine, Calif. Business: Neurological Product: Neotrofin leteprinim (AIT-082) Therapeutic category: Growth factor, Nerve regeneration Description: Small molecule stimulato...